Abattis Bioceuticals Corp. announced earnings results for the full year ended September 30, 2019. For the full year, the company announced sales was CAD 356,876 compared to CAD 8,371 a year ago. Net loss was CAD 3.042 million compared to CAD 78.012 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.24 a year ago.